Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1057519847
rs1057519847
0.010 GeneticVariation BEFREE However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883). 28549835

2017

dbSNP: rs1057519848
rs1057519848
0.010 GeneticVariation BEFREE However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883). 28549835

2017

dbSNP: rs121434568
rs121434568
0.010 GeneticVariation BEFREE However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883). 28549835

2017

dbSNP: rs397517096
rs397517096
0.010 GeneticVariation BEFREE L747P (2239-2240 TT>CC) in exon 19 is a rare EGFR mutation that appears to lead to gefitinib resistance and might accelerate liver metastases. 26339441

2015

dbSNP: rs121434569
rs121434569
0.020 GeneticVariation BEFREE First-line gefitinib, longer EGFR TKI treatment duration, male, initial liver metastasis and uncommon EGFR mutations may be independent factors for secondary EGFR T790M mutation. 30485437

2019

dbSNP: rs121434569
rs121434569
0.020 GeneticVariation BEFREE After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel. 28193529

2017